Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights
November 19, 2019 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting
November 11, 2019 01:00 ET
|
Celyad SA
Results from ongoing, dose-escalation alloSHRINK Phase 1 trial demonstrate absence of graft-versus-host disease for first-in-class, non-gene edited allogeneic CAR-T candidate, CYAD-101, when...
Celyad to Present Update to r/r AML and MDS Program at 2019 ASH Annual Meeting
November 06, 2019 09:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Highlights Abstracts from mCRC Clinical Program Released for SITC 34th Annual Meeting
November 05, 2019 08:00 ET
|
Celyad SA
Management to host webcast on Saturday, Nov. 9, at 12:35 p.m. ET/ 6:35 p.m. CET MONT-SAINT-GUIBERT, Belgium, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq:...
Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting
October 02, 2019 01:00 ET
|
Celyad SA
Poster presentations to highlight allogeneic and autologous NKG2D-based CAR-T therapies for the treatment of advanced metastatic colorectal (mCRC) cancers MONT-SAINT-GUIBERT, Belgium, Oct. 02, 2019 ...
Celyad Announces October and November 2019 Investor Conference Schedule
October 02, 2019 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Announces Closing of $20 Million Global Offering
September 16, 2019 16:01 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Announces Pricing of $20.0 Million Global Offering
September 12, 2019 09:28 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Announces Launch of Proposed Global Offering
September 10, 2019 16:01 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process
September 04, 2019 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...